Life-Changing Medicines.
Redefining Possibilities.
COVID-19 Response Jazz is implementing a robust continuity plan in response to the COVID-19 pandemic. Learn More
patient story
Life Before and After Stem Cell Transplant
After receiving treatment for acute myeloid leukemia, Steve underwent a stem cell transplant to decrease the odds of the cancer returning. Following the transplant, his journey was complicated with a diagnosis of veno-occlusive disease.
Steve and Crystal’s Story
Our science
Understanding Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
There are several types of blood cancer, including acute lymphoblastic leukemia and lymphoblastic lymphoma, which are among the most difficult to treat.
Learn More
News and Events
June 15, 2020
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
June 9, 2020
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
June 8, 2020
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026
Jazz strives to create a workplace culture that supports a diverse, multicultural workforce and provides an inclusive environment where all employees are empowered to contribute and succeed.
See all News
Jazz Pipeline
PRE-CLINICAL
JZP-324
Oxybate once-nightly formulation

CombiPlex
Hem/Onc exploratory activities

JZP-341 (Long-acting Erwinia asparaginase)2
ALL/other hematological malignancies

Recombinant Pegaspargase1
Hematological malignancies

Pan-RAF Inhibitor program
RAF & RAS mutant tumors

Exosome targets (NRAS, STAT3 and 3 others)2
Hematological malignancies/solid tumors

Defibrotide
Exploratory activities

PHASE 1
CPX-351
Low Intensity Dosing for higher risk MDS3

CPX-351 + other approved therapies
  • R/R AML or HMA Failure MDS3
  • First-line, fit AML (Phase 1b)
  • Low Intensity Therapy for first-line, unfit AML (Phase 1b)
IMGN6321
  • R/R CD123+ Hematological malignancies
  • +/- venetoclax/azacitidine in CD123+ AML (Phase 1b/2)

PHASE 2
JZP-3854
Essential tremor (Phase 2b)

Defibrotide
  • Prevention of aGvHD
  • Prevention of CAR-T associated neurotoxicity
CPX-351
  • HR-MDS (EMSCO)5
  • Newly diagnosed older adults with HR-AML4,5
CPX-351 + venetoclax
de novo or R/R AML3

PHASE 3
JZP-258
Idiopathic hypersomnia

JZP-458 (recombinant Erwinia asparaginase)
ALL/LBL (pivotal Phase 2/3)

Lurbinectedin6
Relapsed SCLC (ATLANTIS)

CPX-351
  • AML or HR-MDS >60 yrs (AML18)5
  • AML or HR-MDS >18 yrs (AML19)5
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)5
  • Newly diagnosed pediatric patients with AML (COG)4,5

REGULATORY
JZP-258
Cataplexy & EDS in narcolepsy

Neuroscience
Hematology/Oncology
1Opt-in opportunity
2Partnered collaboration
3Jazz & MD Anderson Cancer Center collaboration study
4Planned
5Cooperative group study
6Exclusive U.S. license

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
More About Jazz
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Our Medicines